Abstract
Single ventricle heart disease is a severe and life-threatening illness, and improvements in clinical outcomes of those with Fontan circulation have not yet yielded acceptable survival over the past two decades. Patients are at risk of developing a diverse variety of Fontan-associated comorbidities that ultimately requires heart transplant. Our observational cohort study goal was to determine if principal component analysis (PCA) applied to data collected from a substantial Fontan cohort can predict functional decline (N=140). Heterogeneous data broadly consisting of measures of cardiac and vascular function, exercise (VO2max), lymphatic biomarkers, and blood biomarkers were collected over 11 years at a single site; in that time, 16 events occurred that are considered here in a composite outcome measure. After standardization and PCA, principal components (PCs) representing >5% of total variance were thematically labeled based on their constituents and tested for association with the composite outcome. Our main findings suggest that the 6th PC (PC6), representing 7.1% percent of the total variance in the set, is greatly influenced by blood serum biomarkers and superior vena cava flow, is a superior measure of proportional hazard compared to EF, and displayed the greatest accuracy for classifying Fontan patients as determined by AUC. In bivariate hazard analysis, we found that models combining systolic function (EF or PC5) and lymphatic dysfunction (PC6) were most predictive, with the former having the greatest AIC, and the latter having the highest c-statistic. Our findings support our hypothesis that a multifactorial model must be considered to improve prognosis in the Fontan population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Jayden DeLuca Foundation, NIH CTSA Grant UL1 TR002535, and the American Heart Association Children?s Heart Foundation Predoctoral Congenital Heart Defect Research Award 20PRE35260057 to MRF.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Colorado Multiple Institutional Review Board (COMIRB) protocol #14-1072, approved 08/11/2023
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author, KSH, upon reasonable request
Abbreviations
- SVD
- single ventricle disease
- PLE
- protein losing enteropathy
- PB
- plastic bronchitis
- FALD
- Fontan-associated liver disease
- PC MRI
- phase contrast magnetic resonance imaging
- VVCR
- ventricular vascular coupling ration
- VO2
- rate of oxygen consumption
- AAo
- ascending aorta
- SVC
- superior vena cava
- IVC
- inferior vena cava
- LPA
- left pulmonary artery
- cMRI
- cardiac MRI
- TCPC
- total cavopulmonary connection
- PCA
- principal component analysis
- PCs
- principal components
- EF
- ejection fraction
- EDVi
- end diastolic volume index
- ESVi
- end systolic volume index
- CI
- cardiac index
- BNP
- B-type natriuretic peptide
- GGT
- gamma-glutamyl transferase
- AST
- aspartate aminotransferase
- SaO2
- arterial oxygen saturation
- FEV1
- forced expiratory volume in one second
- mSVCP
- mean SVC pressure
- mPAP
- mean pulmonary artery pressure
- HLHS
- hypoplastic left heart syndrome
- TA
- tricuspid atresia
- DORV
- double outlet right ventricle
- DILV
- double inlet left ventricle
- HRHS
- hypoplastic right heart syndrome
- TCPC
- total cavopulmonary circuit
- FVC
- forced vital capacity
- RV
- residual volume
- TLC
- total lung capacity
- Alk phos
- alkaline phosphatase
- BUN
- blood urea nitrogen